VYNE Therapeutics (VYNE) Competitors $0.35 -0.01 (-3.47%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.60%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. ORMP, ARTV, XBIT, ENTX, MIST, CABA, QNCX, JMAC, EXOZ, and EPIXShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Oramed Pharmaceuticals (ORMP), Artiva Biotherapeutics (ARTV), XBiotech (XBIT), Entera Bio (ENTX), Milestone Pharmaceuticals (MIST), Cabaletta Bio (CABA), Quince Therapeutics (QNCX), Maxpro Capital Acquisition (JMAC), eXoZymes (EXOZ), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Oramed Pharmaceuticals Artiva Biotherapeutics XBiotech Entera Bio Milestone Pharmaceuticals Cabaletta Bio Quince Therapeutics Maxpro Capital Acquisition eXoZymes ESSA Pharma Oramed Pharmaceuticals (NASDAQ:ORMP) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Do analysts recommend ORMP or VYNE? VYNE Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 1,671.04%. Given VYNE Therapeutics' higher possible upside, analysts clearly believe VYNE Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, ORMP or VYNE? Oramed Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Does the media refer more to ORMP or VYNE? In the previous week, VYNE Therapeutics had 8 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 14 mentions for VYNE Therapeutics and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of -0.14 beat VYNE Therapeutics' score of -0.54 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Negative Is ORMP or VYNE more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. Oramed Pharmaceuticals' return on equity of -11.34% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -11.34% -10.73% VYNE Therapeutics -6,974.55%-71.89%-58.94% Do insiders and institutionals hold more shares of ORMP or VYNE? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, ORMP or VYNE? Oramed Pharmaceuticals has higher revenue and earnings than VYNE Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M64.63-$19.06M-$0.44-4.82VYNE Therapeutics$500K10.74-$39.83M-$0.99-0.36 SummaryOramed Pharmaceuticals beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.56M$2.50B$5.48B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.368.9728.8623.83Price / Sales10.74436.67371.7266.14Price / CashN/A157.7635.4557.96Price / Book0.104.838.275.54Net Income-$39.83M$31.62M$3.25B$259.28M7 Day Performance-75.83%-5.28%-3.73%-4.68%1 Month Performance-76.63%4.38%4.29%4.36%1 Year Performance-80.39%-2.49%25.87%17.89% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.542 of 5 stars$0.35-3.5%$6.25+1,671.0%-80.6%$5.56M$500K-0.3630Trending NewsAnalyst DowngradeGap DownORMPOramed Pharmaceuticals0.5957 of 5 stars$2.21+2.3%N/A-10.5%$88.22M$1.34M-5.0210News CoveragePositive NewsAnalyst RevisionARTVArtiva Biotherapeutics2.1345 of 5 stars$2.96-17.8%$17.80+501.4%-75.6%$87.71M$250K0.0081News CoverageUpcoming EarningsXBITXBiotech0.9764 of 5 stars$2.82-1.7%N/A-61.0%$87.50M$4.01M-2.19100News CoveragePositive NewsShort Interest ↑ENTXEntera Bio2.6256 of 5 stars$2.06+10.8%$10.00+385.4%+21.1%$84.54M$180K-7.9220News CoveragePositive NewsUpcoming EarningsGap UpHigh Trading VolumeMISTMilestone Pharmaceuticals1.8266 of 5 stars$1.55-1.9%$7.00+351.6%+2.9%$84.47MN/A-1.9930Positive NewsUpcoming EarningsShort Interest ↑CABACabaletta Bio1.8014 of 5 stars$1.69+1.8%$14.43+753.8%-79.1%$84.23MN/A-0.6750Upcoming EarningsQNCXQuince Therapeutics2.4373 of 5 stars$1.80-2.7%$8.00+344.4%+125.9%$84.12MN/A-1.2960Negative NewsShort Interest ↑JMACMaxpro Capital AcquisitionN/A$6.23+1.3%N/A+2,963.2%$83.66MN/A0.002,021News CoverageEXOZeXoZymesN/A$9.93-0.5%N/AN/A$83.51M$70K0.0029EPIXESSA Pharma1.1894 of 5 stars$1.87-0.5%$2.00+7.0%-63.4%$83.45MN/A-2.9750News CoverageUpcoming Earnings Related Companies and Tools Related Companies ORMP Competitors ARTV Competitors XBIT Competitors ENTX Competitors MIST Competitors CABA Competitors QNCX Competitors JMAC Competitors EXOZ Competitors EPIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYNE Stock Alerts